Statin With Palliative Therapy for HCC
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 4
- 试验地点
- 1
- 主要终点
- Overall Survival
研究概览
简要总结
Statin is a preventive medicine for hepatitis B and hepatitis C which decreases the risk turning into liver cancer,however, the investigators also discovered that patients taking Statin live longer than patients who didn't take Statin in the incidence of liver cancer death cases.
详细描述
Most liver cancer patients did not accept the cure as the main objective of the treatment after diagnosis because they choose alternative therapies palliative based, such as hepatic arterial chemoembolization, chemotherapy and radiation therapy.
Statin is a preventive medicine for hepatitis B and hepatitis C which decreases the risk turning into liver cancer, yet the clinical effect for Statin is still unknown.
In a previous study of 20,220 liver cancer patients in health care database, the investigators discovered that patients taking Statin live longer than patients who didn't take Statin in the incidence of liver cancer death cases.
This study is a continuation of previous health insurance database studies for clinical trials to verify whether Statin could prolong disease-free survival role for palliative treatment of liver cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 20 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •>20 years old.
- •BCLC stage B , stage C and stage D
排除标准
- •Cancer diagnosis before HCC was confirmed and incurable.
- •<20 years old, > 90years old.
- •Patients who are judged to be ineligible for study entry by the investigator or subinvestigator
研究组 & 干预措施
Statin(Crestor) taken
Subjects take Statin(Crestor) 10mg per day for a- year
干预措施: Statin (Drug)
结局指标
主要结局
Overall Survival
时间窗: Up to two year
次要结局
未报告次要终点